
    
      Study design. Interventional, open-label, 2-week, prospective trial of a cohort of patients
      with mild to moderate COVID-19 infection.

      Objectives. Primary. To assess the efficacy of baricitinib combined with antiviral therapy in
      patients with COVID-19-related mild and moderate disease in terms of reduction of the
      percentage of subjects requiring ICU admission.

      Secondary objectives. To describe the clinical findings in a cohort of symptomatic
      COVID-19-infected subjects; to investigate the role of CRP, IL-6, and TNFÎ± levels as
      predictor of progression to ARDS; to assess the type and incidence of adverse events (AEs).
    
  